A life-sciences organization can have validated equipment, approved procedures, and a quality unit and still be unable to release a batch, complete a critical test, or keep a multi-site laboratory network running if a contract manufacturer, a specialized testing lab, a cloud laboratory system, or a model used in development or quality cannot perform. In that moment the problem is not only a supplier-management finding. It is a continuity problem, a quality problem, and, where models are in the path, an AI-governance problem.
Life sciences is not a single regulatory silo. Drug and biological product manufacturers, blood and biologics laboratories, and medical-device firms live under different Food and Drug Administration frameworks, and many also sell or operate in the European Union. This article does not treat those frameworks as interchangeable, and it does not invent client or facility examples. It asks how third-party risk and AI should be governed so that testing, manufacturing, and release can continue when a partner or a model fails.

